NRx Pharmaceuticals (NASDAQ:NRXP) Earns “Buy” Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $34.00 price target on the stock.

A number of other brokerages have also issued reports on NRXP. Zacks Research raised NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Finally, Ascendiant Capital Markets raised their price target on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NRx Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $34.75.

NRx Pharmaceuticals Stock Up 3.1%

Shares of NASDAQ NRXP traded up $0.08 during trading on Tuesday, reaching $2.47. 244,367 shares of the stock were exchanged, compared to its average volume of 489,283. The company has a market capitalization of $69.26 million, a price-to-earnings ratio of -1.04 and a beta of 1.76. The business’s 50-day moving average price is $2.86 and its 200 day moving average price is $2.89. NRx Pharmaceuticals has a twelve month low of $1.15 and a twelve month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $6.83 million. As a group, sell-side analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after purchasing an additional 993,401 shares during the last quarter. Vanguard Group Inc. boosted its position in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the period. AdvisorShares Investments LLC grew its stake in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares during the last quarter. Geode Capital Management LLC grew its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the period. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.